ICB International
Business Services · California, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
505 Coast Blvd S Ste 405, La Jolla, Cali...Phone Number
(858) 455-9880Website
www.icbii.comRevenue
$10.6 MillionIndustry
About ICB International
ICBI specializes in developing breakthrough therapeutic drugs using its proprietary SMART Molecule Technology Platform, which enables the delivery of treatments across the blood-brain barrier for neurodegenerative disorders like Alzheimer's and Parkinson's disease. The company aims to address the needs of the 65 million individuals globally affected by these diseases, with a focus on early diagnosis, monitoring, and treatment. ICBI's innovative biologics target pathological proteins in the central nervous system, offering significant clinical potential. Established in 2008, ICBI has garnered respect in the scientific community through extensive research and numerous patents.Explore more
ICB International Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to ICB International
Compare insights from companies similar to ICB International, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
<$5M
11-50
Private
<$5M
2005
CL
Cynthia LevinthalPrincipal Consultant. Neural Stem Cell Therapies. Clinical Trials
ICB International Tech Stack
A closer look at the technologies used by ICB International
See more technologies
Top Business Services Companies
Frequently Asked Questions Regarding ICB International
Sign Up For FreeTo access detailed company insights
ICBI specializes in developing breakthrough therapeutic drugs using its proprietary SMART Molecule Technology Platform, which enables the delivery of treatments across the blood-brain barrier for neurodegenerative disorders like Alzheimer's and Parkinson's disease. The company aims to address the needs of the 65 million individuals globally affecte... Read More
